Use of IMSI in Poor Responders to IVF

Use of Intra-Cytoplasmic Morphologically Selected Sperm Injection (IMSI) in Poor Responders to In Vitro Fertilization (IVF): a Prospective, Double-blind, Randomized, Controlled Trial

This is a pilot study which aims to determine the role of IMSI in poor responders.

This is a pilot study which aims to determine the role of IMSI over ICSI in poor responders to IVF, without a background of teratozoospermia.

Inclusion Criteria:

• poor ovarian response

Exclusion Criteria:

• body mass index (BMI) ≥ 30 kg/m2
• presence of endocrinopathies (e.g., diabetes, hyperprolactinemia, hypothyroidism)
• altered karyotype or documented genetic defects in one or both partners
• history of chronic, autoimmune or metabolic diseases
• altered meiosis in testicular biopsy or altered sperm-FISH
• teratozoospermia
• participation, simultaneously or within the previous 6 months, in another clinical trial with medication